Skip to content

Evaluation of the effects of intra-articular injection of platelet-rich plasma (PRP) on patients with knee osteoarthritis

Evaluation of the effects of intra-articular injection of platelet-rich plasma (PRP) on pain and function of patients with knee osteoarthritis and comparison of the efficacy between moderate and severe degrees of knee osteoarthritis based on the Kellgren Lawrence classification

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250305064943N1
Enrollment
82
Registered
2025-05-02
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention group: intraarticlar injection of PRP in knee.

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: People between 40 and 80 years old. People with knee pain who have a VAS score of at least 4 on a standing knee radiograph and at least grade 2 osteoarthritis according to the Kellogg-Lawrence criteria, and who have received supportive treatment for at least 3 months and have not responded to treatment.

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Active cancer active infectious disease Drug or drug addiction History of any knee surgery or major trauma (leading to traumatic injury to the ligaments or meniscus or articular cartilage) Blood and coagulation diseases and use of anticoagulants Known rheumatological disease and fibromyalgia Use of anti-inflammatory medications and supplements (NSAIDs, corticosteroids, vitamins E and C, curcumin, and omega-3) within a week before and after the injection Having a significant physical or mental illness that increases the risk of disruption to the study process History of receiving corticosteroids or PRP in the knee for at least the past 6 months Use of any analgesics and physiotherapy modalities within 72 hours prior to outcome assessment

Design outcomes

Primary

MeasureTime frame
WOMAC questionnaire score. Timepoint: First visit, two months, and 6 months after the second injection. Method of measurement: WOMAC questionnaire.;Pain(VAS). Timepoint: First visit, two months, and 6 months after the second injection. Method of measurement: Patients are asked to rate the overall pain intensity they experienced over the past 48 hours on a Visual Analogue Scale (VAS) from 1 to 100.

Secondary

MeasureTime frame
The 30 Second Sit to Stand Test. Timepoint: First visit and two months after the second injection. Method of measurement: the number of times a person can stand and sit without using the arm of a chair in 30 seconds.;40 metre fast-paced walk test. Timepoint: First visit and two months after the second injection. Method of measurement: The time it takes for a person to walk a distance of 40 meters at maximum speed without running.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeideh Soltani

Tehran University of Medical Sciences

ss.soltaniiii@gmail.com+98 21 6119 5270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026